Residual microvascular risk in diabetes: unmet needs and future directions

Area of Science:

• Endocrinology and Metabolism
• Cardiovascular Research
• Ophthalmology

Background:

• Type 2 diabetes mellitus (T2DM) is a global health crisis with escalating microvascular disease burden.
• Current treatments for T2DM do not fully eliminate risks of retinopathy, nephropathy, and neuropathy.
• Atherogenic dyslipidemia, marked by high triglycerides and low HDL cholesterol, is a key factor in residual microvascular risk.

Purpose of the Study:

• To review the current understanding of microvascular residual risk in T2DM.
• To highlight the potential benefits of managing dyslipidemia for reducing microvascular complications.
• To emphasize the need for further research into optimal management strategies for residual risk.

Main Methods:

• Review of existing literature on T2DM microvascular complications.
• Analysis of studies investigating lipid-modifying therapies (fibrates, statins) for diabetic complications.
• Discussion of ongoing epidemiological studies to identify risk factors.

Main Results:

• Promising data exist for fibrate therapy in diabetic maculopathy and retinopathy.
• Statin or fibrate therapy shows potential for diabetic nephropathy.
• Optimal care currently fails to halt progression in diabetic peripheral neuropathy, underscoring residual risk.

Conclusions:

• Managing atherogenic dyslipidemia may offer additional benefits beyond glucose control in T2DM.
• Further studies are essential to define optimal strategies for mitigating residual microvascular risk.
• Addressing residual risk is a priority, especially for diabetic peripheral neuropathy.